NCT01499108View on ClinicalTrials.gov

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2014

Conditions

Type 2 Diabetes

Interventions

DRUG

liraglutide

Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study

Trial Locations (1)

2820

Steno Diabetes Center, Gentofte Municipality

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Peter Rossing

OTHER